Revenue Recognition

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Abstract]

Revenue Recognition

. Revenue Recognition

To date, our only source of revenue has been from the U.S. sales of VOQUEZNA products, which the Company began selling during the fourth quarter of 2023. The Company records its best estimate of chargebacks, sales discounts and other reserves to which customers are likely expected to be entitled to as contra accounts receivable charges, and within accrued expenses if payable to a third-party or related to product returns on the balance sheets. During the years ended December 31, 2025 and 2024, the Company recognized $175.1 million and $55.3 million, respectively, of net product revenues related to sales of VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK.

The following table provides a summary of the Company's revenue allowances and related accruals for the year ended December 31, 2025 which have been deducting in arriving at product revenues, net (in thousands):

	Customer Credits, Discounts and Allowances			Rebates, Returns and Co-Pay Assistance
	(contra accounts receivable)			(accrued expenses)			Total
Balance as of January 1, 2025	$	5,659		$	29,987		$	35,646
Accruals		65,653			174,330			239,983
Utilizations		(60,666	)		(138,855	)		(199,521	)
Balance as of December 31, 2025	$	10,646		$	65,462		$	76,108